Subscribe To
TSHA / Taysha Gene Therapies Gets A 'Thumbs Up'
TSHA News
By Seeking Alpha
November 3, 2023
Taysha Gene Therapies: TSHA-102's Potential Is A 'Buy'
Taysha Gene Therapies is a biotech stock focused on developing gene therapies for monogenic CNS diseases, with its lead candidate TSHA-102 targeting R more_horizontal
By Zacks Investment Research
September 5, 2023
Taysha Gene Therapies, Inc. (TSHA) Just Flashed Golden Cross Signal: Do You Buy?
Taysha Gene Therapies, Inc. (TSHA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, more_horizontal
By Seeking Alpha
May 11, 2023
Taysha Gene Therapies, Inc. (TSHA) Q1 2023 Earnings Call Transcript
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Hayleigh Collins - Director a more_horizontal
By Seeking Alpha
March 28, 2023
Taysha Gene Therapies, Inc. (TSHA) Q4 2022 Earnings Call Transcript
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q4 2022 Earnings Conference Call March 28, 2023 4:30 PM ET Company Participants Hayleigh Collins - Director more_horizontal
By PennyStocks
November 21, 2022
Best Penny Stocks To Buy Now? 5 Biotech Stocks To Watch This Week
Biotech penny stocks to watch this week. Are they a buy now? more_horizontal
By Seeking Alpha
November 17, 2022
Taysha Gene Therapies: Astellas Throws Lifeline For First Dibs On Rett And GAN Programs
Shares have fallen by 85% since Sept 2020 IPO as cash resources dwindled to $34M as of last month. Company was forced to cut 35% of workforce, stop co more_horizontal
By Seeking Alpha
November 13, 2022
Taysha Gene Therapies, Inc. (TSHA) Q3 2022 Results - Earnings Call Transcript
Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q3 2022 Results Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Kimberly Lee - Ch more_horizontal
By GlobeNewsWire
August 9, 2022
Taysha Gene Therapies to Release Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11
DALLAS, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on more_horizontal